Epirubitec 50mg Injection
Marketer
United Biotech Pvt Ltd
Salt Composition
Epirubicin (50mg)
Overview Epirubitec 50mg Injection
Epirubitec 50mg injection treats various hematologic malignancies, as well as cancers affecting the breast, stomach, lung, ovaries, and soft tissues. It also aids in preventing bladder cancer recurrence post-surgery. Administered intravenously by a healthcare professional, it's used alone or in combination chemotherapy regimens. Dosage and frequency are determined by your physician based on your specific condition and may vary. Strict adherence to prescribed instructions is crucial, as improper use or overdose can lead to severe adverse effects. Therapeutic benefits might not be apparent immediately; discontinue use only under medical guidance. Note that it reduces contraceptive efficacy; reliable birth control is recommended for both partners during treatment. Common side effects include nausea, thrombocytopenia, alopecia, amenorrhea, pyrexia, and skin rashes. The drug's effect on blood cell counts increases infection risk, potentially life-threatening. Regular blood tests, along with kidney, liver, and heart function monitoring, are essential. Prior to treatment, disclose any liver or heart conditions, and provide a complete list of current medications, as interactions can impact Epirubitec's efficacy. Inform your doctor of pregnancy or breastfeeding.
Uses of Epirubitec 50mg Injection
Malignant neoplasm
Major Benefits of Epirubitec 50mg Injection:
Administering this medication will be handled by your healthcare provider. Self-medication is strongly discouraged.
Common Side effects of Epirubitec 50mg Injection:
- Low blood platelets
- Nausea
- Hair loss
- Absence of menstrual periods
- Fever
- Anemia (low number of red blood cells)
- Diarrhea
- Weight loss
- Decreased white blood cell count (neutrophils)
- Hot flashes
- Gastrointestinal inflammation
- Rash
- Low energy
- Eye disorder
How to use Epirubitec 50mg Injection:
The medication will be administered by your healthcare provider. Self-medication is strictly prohibited.
How Epirubitec 50mg Injection works:
The anti-neoplastic agent, Epirubitec 50mg Injection, targets breast cancer cells by inhibiting topoisomerase II, an enzyme crucial for DNA replication. Its mechanism of action also includes the generation of cytotoxic free radicals, inducing DNA damage. This dual approach restricts cancerous cell proliferation and leads to their demise.
SAFETY ADVICE
AlcoholUNSAFE
Combining Epirubitec 50mg Injection and alcohol is strongly discouraged due to safety concerns.
PregnancyCONSULT YOUR DOCTOR
Administering Epirubitec 50mg Injection during pregnancy poses a confirmed risk to the fetus. Therefore, its use is contraindicated. Nevertheless, in exceptional life-threatening circumstances, a physician might deem its use justifiable if the potential benefits outweigh the inherent dangers. Always seek medical advice.
Breast feedingUNSAFE
Administration of Epirubitec 50mg Injection is contraindicated while breastfeeding due to potential infant toxicity. Studies indicate a risk of harm to the nursing infant.
DrivingUNSAFE
Administering Epirubitec 50mg Injection may induce adverse reactions impacting driving aptitude. Nausea and vomiting, potential side effects of Epirubitec 50mg Injection, can temporarily hinder driving capabilities.
KidneySAFE IF PRESCRIBED
Epirubitec 50mg Injection appears safe for individuals with impaired kidney function. Current evidence indicates dose modification for Epirubitec 50mg Injection might be unnecessary in such cases. However, medical advice is recommended. A reduced dosage may be warranted for patients exhibiting serum creatinine levels exceeding 5 mg/dL.
LiverCAUTION
Patients with liver impairment should receive Epirubitec 50mg Injection cautiously, potentially requiring a modified dosage. Consult a physician before use. Epirubitec 50mg Injection is contraindicated in individuals with severe hepatic dysfunction.
What if you forget to take Epirubitec 50mg Injection :
NA
Facts to Know About Epirubitec 50mg Injection
| Label | Value |
|---|---|
| Chemical Type | Anthracycline-based drug |
| Developing Habits | No. |
| Type of Therapy | Cancer Medications |
| Actions | Cytotoxic alkaloids |
3,018 People bought this recently